PVLA

Palvella Therapeutics, Inc

NASDAQ: PVLA · HEALTHCARE · BIOTECHNOLOGY

$146.33

+0.12% today

Updated 2026-11-02

Market cap

$2.11B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.85

Dividend yield

—

52W range

$72 – $161

Volume

0.2M

Market cap

$2.11B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.85

Dividend yield

—

52W range

$72 – $161

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-3.7

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →253 stocks currently score above 75

Price targets

Analyst target

$228.40

+56.09%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy15 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.00x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -3.68 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-12.85M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$25.90M	$0.00	$0.00	$0.00	$0.00
Net income	$-33.28M	$18.69M	$-17.43M	$-41.72M	$-21.87M
EPS	—	—	—	—	$-4.85
Free cash flow	$-15.88M	$-13.70M	$-10.84M	$-25.01M	$-12.85M
Profit margin	-128.47%	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
PVLA	$2.11B	25	4.3	3.0	5.0	6.0	—	Avoid
LLY	$1.26T	74	9.3	10.0	5.0	6.0	—	Strong Buy
JNJ	$657.68B	54	4.7	8.5	2.7	5.5	-89.35%	Buy
ABBV	$521.11B	77	6.7	9.0	4.0	5.0	-88.02%	Strong Buy
MRK	$368.89B	44	3.3	6.5	2.0	5.0	-76.61%	Hold
UNH	$365.29B	62	6.7	6.0	4.7	5.5	-24.78%	Buy

Smart narrative

Palvella Therapeutics, Inc trades at $146.33. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -3.68, it sits in the distress.

Frequently asked questions

What is Palvella Therapeutics, Inc's stock price?

Palvella Therapeutics, Inc (PVLA) trades at $146.33.

Is Palvella Therapeutics, Inc overvalued?

Palvella Therapeutics, Inc carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Palvella Therapeutics, Inc (PVLA)?

The 12-month analyst consensus target is $228.40, about 56.1% above the current $146.33. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Palvella Therapeutics, Inc's Altman Z-Score is -3.68, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-21.22%

Beta—

50D MA$141.47

200D MA$126.93

Shares out0.01B

Float0.01B

Short ratio—

Avg volume0.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

PVLA vs LLY →PVLA vs JNJ →PVLA vs ABBV →Stock screener →